Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9423866 | 0.89 | FAAH (0.42) | FAAHTSHRALDH1A1DNM1ZDHHC20 | |
| SCHEMBL5823693 | 0.86 | TSHR (0.37) | FAAHTSHRALDH1A1DNM1ZDHHC20 | |
| SCHEMBL170586 | 0.79 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL7681528 | 0.79 | FAAH (0.39) | FAAHTSHRALDH1A1DNM1ZDHHC20 | |
| SCHEMBL5365307 | 0.79 | FAAH (0.36) | FAAHTSHRALDH1A1DNM1 | |
| Hydrochloric Acid SCHEMBL28784380 | 0.77 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL4551351 | 0.77 | TSHR (0.39) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL15477589 | 0.75 | TSHR (0.43) | FAAHTSHRALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL11617998 | 0.75 | TSHR (0.35) | FAAHTSHRALDH1A1 | |
| SCHEMBL3674964 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | P2RY1, P2RY4, P2RY2 | FAAH 4225/4885TSHR 490/4885ALDH1A1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.